Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Birmingham, AL
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Phoenix, AZ
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Santa Clara, CA
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Aurora, CO
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Bridgeport, CT
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Washington,
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Decatur, GA
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Honolulu, HI
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Park Ridge, IL
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Louisville, KY
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Metairie, LA
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Baltimore, MD
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Jackson, MS
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
St. Joseph, MO
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Helena, MT
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Helena, MT
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Newark, NJ
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
New York, NY
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Ashville, NC
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Cleveland, OH
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Philadelphia, PA
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Chattanooga, TN
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Dallas, TX
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Norfolk, VA
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated:  1/30/2013
Clinical Research Facility
mi
from
Seattle, WA
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Phase III in Partial and Null Responders
Status: Enrolling
Updated: 1/30/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Birmingham, AL
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Santa Clara, CA
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Bridgeport, CT
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Decatur, GA
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Park Ridge, IL
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Baltimore, MD
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Lebanon, NH
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
New York, NY
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Dallas, TX
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Norfolk, VA
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated:  2/1/2013
Clinical Research Facility
mi
from
Seattle, WA
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Status: Enrolling
Updated: 2/1/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated:  2/26/2013
Kaiser Permanente Infectious Diseases, Antelope Valley
mi
from
Lancaster, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated: 2/26/2013
Kaiser Permanente Infectious Diseases, Antelope Valley
mi
from
Lancaster, CA
Click here to add this to my saved trials
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated:  2/26/2013
Veterans Administration Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated: 2/26/2013
Veterans Administration Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated:  2/26/2013
University of California, Los Angeles, School of Medicine
mi
from
Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated: 2/26/2013
University of California, Los Angeles, School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated:  2/26/2013
AIDS Healthcare Foundation
mi
from
Los Angeles, CA
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
Status: Enrolling
Updated: 2/26/2013
AIDS Healthcare Foundation
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV
Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV
Status: Enrolling
Updated:  2/28/2013
Rockefeller University
mi
from
New York, NY
Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV
Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV
Status: Enrolling
Updated: 2/28/2013
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
3 Grams Daily Valacyclovir in Chronic Hepatitis C Infection (Phase II)
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase II)
Status: Enrolling
Updated:  3/5/2013
G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS
mi
from
Jackson, MS
3 Grams Daily Valacyclovir in Chronic Hepatitis C Infection (Phase II)
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase II)
Status: Enrolling
Updated: 3/5/2013
G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated:  3/6/2013
Clinical Research Facility
mi
from
Birmingham, AL
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated:  3/6/2013
Clinical Research Facility
mi
from
Dothan, AL
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated:  3/6/2013
Clinical Research Facility
mi
from
Bakersfield, CA
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated:  3/6/2013
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated:  3/6/2013
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated:  3/6/2013
Clinical Research Facility
mi
from
Aurora, CO
A Study to Evaluate Chronic Hepatitis C Infection
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials